FTC goes after PBMs, warns of legal action

Forbes

2 July 2022 - Last month, the Federal Trade Commission voted unanimously (5-0) to examine rising list prices of insulin, but also to probe possible anti-competitive practices by pharmacy benefit managers with respect to the use of rebate arrangements. 

Rebates are payments from drug manufacturers to PBMs in exchange for moving market share towards preferred products on the formulary. 

The Federal Trade Commission cites instances in which cheaper generics and biosimilars are excluded from pharmacy benefit manager formularies, as this may violate competition and consumer protection laws.

Read Forbes article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Pricing , Pharmacy